Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lenograstim × Lymphoid × Clear all

Phase

Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1 Genitourinary 1

Conditions

Multiple Myeloma 1 Hodgkin Disease 1

Interventions

Cyclophosphamide 24 Etoposide 15 Rituximab 14 Cytarabine 13 Vincristine 12 Methotrexate 12 Prednisone 10 Doxorubicin 10 Dexamethasone 10 Radiotherapy 8 Filgrastim 7 Mercaptopurine 6 Daunorubicin 6 Asparaginase 6 pegaspargase 5 fludarabine 5 Granulocyte Colony-Stimulating Factor 5 Drug Therapy 5 Dasatinib 5 blinatumomab 4 Methylprednisolone 4 Busulfan 4 venetoclax 3 ruxolitinib 3 prednylidene 3 fludarabine phosphate 3 etoposide phosphate 3 deltacortene 3 Trimethoprim, Sulfamethoxazole Drug Combination 3 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01085058 2010-03-11

CU01

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2/3 Completed

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡